Home > Healthcare & Medical Devices > Over the Counter (OTC) Drugs Market

Over the Counter (OTC) Drugs Market Size By Product (Analgesics, Cold, Cough & Flu Products, Weight Loss Products, Gastrointestinal Products, Skin Products, Minerals and Vitamin Supplements, Sleeping Aids, Ophthalmic Products), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Medstores), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI1884
  • Published Date: Dec 2022
  • Report Format: PDF

Industry Statistics

OTC Drugs Market size reached more than USD 162 billion in 2022 and is anticipated to exhibit over 5% CAGR from 2023-2032.
 

A steady shift from Rx, or doctor’s prescribed drugs to OTC drugs across pharmaceutical companies in developing nations, notably the U.S. will complement industry growth. Pharma giants are rapidly switching to OTC models allowing drug stores to compensate for the revenue losses rendered by patent expiry concerns pertaining to Rx. OTC has many benefits such as easy off-the-shelf availability, cost effectivity, and improved accessibility.
 

Get more details on this report - Request Free Sample PDF
 

Growing concerns associated with substance abuse and incorrect diagnosis may impede the sale of OTC drugs. While OTC drugs are safe if consumed in the recommended dosage, they can be easily abused like illegal prescription drugs. Drug abuse is a big concern across several countries as it increases the risk of kidney failure, memory loss, and heart problems, and can even be fatal in some cases.
 

Rising prevalence of digestive disorders to boost demand for OTC gastrointestinal drugs

Get more details on this report - Request Free Sample PDF
 

Over the counter drugs market from gastrointestinal products is estimated to surpass USD 25 billion by 2032. Rising incidences of gastrointestinal disorders due to unhealing lifestyles and dietary habits will pave the way for OTC drugs. Over the last couple of decades, the number of digestive cancer cases has increased by 26%, whereas mortality has escalated by 17%.  Heartburn, constipation, nausea, and other conditions caused by current-day lifestyle choices are accelerating the demand for gastrointestinal products such as laxatives, and antacids.
 

High preference toward retail pharmacies for OTC drugs to augment industry statistics

Get more details on this report - Request Free Sample PDF
 

Retail pharmacy segment held over 43% share of the OTC drugs market in 2022. Retail pharmacies are available in significant numbers across the globe. These drug stores are the primary centers that meet the healthcare and pharmaceutical needs of people at an affordable cost. Retail pharmacies enable access to a wide variety of OTC as well as prescription drugs along with free consultation. With increasing efforts to boost the accessibility and infrastructure of healthcare, several countries are investing in retail pharmacies. Additionally, a rise in collaborations between healthcare entities will proliferate industry progress.
 

Solid footprint of drug stores to augment APAC market expansion

Get more details on this report - Request Free Sample PDF
 

Asia Pacific over the counter drugs market is poised to reach over USD 108 billion by 2032. Increasing demand for non-prescription drugs to avoid hospital visits will positively impact the industry growth in APAC. Countries such as India, Japan, and China have emerged as potential landscapes promising medical tourism over the last few years. India is being recognized as a robust world pharmacy sphere with substantial investments in healthcare infrastructure and a rising number of drug stores across the country.
 

New acquisitions to boost industry development

Some of the leading companies in the global over the counter drugs market include Bayer AG, GlaxoSmithKline Plc., Sanofi, Johnson & Johnson Services Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Limited., Cipla, Inc., Reckitt Benckiser Group Plc., Piramal Enterprises Limited, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., The Blackstone Group, Inc. (Alinamin Pharmaceutical Co., Ltd.), Aytu Biopharma, Inc. (Aytu Consumer Health, Inc.), Dr. Reddy's Laboratories, Viatris, Inc.
 

Impact of COVID-19 pandemic on the OTC drugs market trends

The COVID-19 pandemic had a positive impact on the OTC industry with the increasing trend of self-medication and preventative care. The pandemic accelerated consumer inclination toward non-prescription drugs to address several general health conditions in home settings. Due to the higher risk of infection at hospitals and clinics, individuals adopted preventative and self-medication options. This scenario amplified the demand for OTC mineral and vitamin supplements owing to rising awareness regarding the need for immunity boosters during the pandemic.

 

Over the Counter Drugs Market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

By Product

  • Analgesics
  • Cold, cough & flu products
  • Weight loss products
  • Gastrointestinal products
  • Skin products
  • Mineral and vitamin supplements
  • Sleeping aids
  • Ophthalmic products
  • Others

By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • Online medstores
  • Others

 

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Poland
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Taiwan
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Others
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Qatar
    • Kuwait
    • Nigeria
    • Others

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market size for OTC drugs reached over USD 162 billion in 2022 and is anticipated to exhibit over 5% CAGR from 2023-2032
Gastrointestinal products is estimated to surpass USD 25 billion by 2032 owing to the rising prevalence of digestive disorders.
Asia Pacific Over the Counter drugs market size is poised to reach over USD 108 billion by the end of 2032 driven by the rising geriatric population and growing inclination toward non-prescription drugs.
Bayer AG, Sanofi, Johnson & Johnson Services Inc., Cipla, Inc., Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Viatris, Inc. are some of the leading companies in the market.

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 15
  • Tables & Figures: 169
  • Countries covered: 23
  • Pages: 151
  • Upcoming Report: Details can be customized to meet your information and data needs. Feel free to share your detailed research requirements via this form.

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount